SARS-CoV-2 - Tocilizumab - Therapeutic Candidates

SARS-CoV-2 - Tocilizumab - Therapeutic Candidates

 

Tocilizumab is a humanized monoclonal antibody that blocks the action of interleukin-6 (IL-6) receptors. The IL-6 receptor has two forms: the membrane form mIL6R and the soluble form sIL-6R. Tocilizumab can bind specifically to sIL-6R and mIL-6R and inhibit the transduction signal. It is commonly used in rheumatoid arthritis as it is immunosuppressive.
Since the beginning of the COVID-19 pandemic, it has been shown that in patients severely affected by COVID-19 caused by the SARS-CoV-2 virus, there was a "cytokine storm" that would be a major cause of mortality as the inflammatory overreaction would destroy tissues.
IL-6 is thought to be one of the mediators of the inflammation that follows the immune response against SARS-CoV-2 in the pulmonary alveoli and thus one of the cytokines responsible for this "cytokine storm" phenomenon.  Tocilizumab may therefore be a good candidate for treatment of COVID-19.

 

 

Search result : 123 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 45
  • Biotin 1
  • human 41
  • monkey 5
  • mouse 1
  • rat 1
  • human 8
  • mouse 6
  • rabbit 2
  • rat 1
  • Primary antibody 60
  • ELISA/ELISPOT 23
  • Biochemicals 19
  • kit 16
  • Inhibitor/Antagonist/Agonist 4
  • Protein/peptide 1
  • ELISA 43
  • FC 10
  • Assay 2
  • IF 2
  • Inhibition assay 2
  • Quant 2
  • Blocking 1
  • FA 1
  • Qual 1
  • Monoclonal 26
  • 6
  • rhPM-1 (Tocilizumab) 6
  • Polyclonal 4
  • 6C10 3
  • 14B10 2
  • rhPM-1 2
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
T9911-2mg
 2mg 
T9911-100mg
 100mg 
T9911-1mg
 1mg 
T9911-25mg
 25mg 
T9911-5mg
 5mg 
T9911-10mg
 10mg 
T9911-50mg
 50mg 
EAD-Toci-5
 5PlateKit 
EAD-Toci-2
 2PlateKit 
EAD-Toci-1
 1PlateKit 
592265-100ug
 100ug 
HY-P9917-5mg
 5mg 
DA-Tocilizumab-200
 200tests